A study of U.S. health records published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who were prescribed GLP-1 receptor agonists had a 24% lower risk of psychiatric hospital admission than those not taking GLP-1s

From the articleGLP-1s and schizophrenia: Drug is linked to lower need for acute care in patients with schizophrenia and type 2 diabetes, study suggestsAlso in GLP-1 Drugs Cut Schizophrenia Hospital Visits, Study Finds